/**/ RNS Number : 8077J IQ-AI Limited 18 August 2023   18 August 2023 IQ-AI Ltd (“IQ-AI” or the “Company”)   IB and GE HealthCare Enter into Commercial Agreement   IB Neuro and IB Delta T1 to be embedded in GE HealthCare’s (GEHC) MR Smart Subscription   Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of

/**/ RNS Number : 5460J IQ-AI Limited 17 August 2023   17 August 2023 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2023 The Board of IQ-AI Ltd is pleased to announce the Company’s half yearly report for the period ended 30 June 2023. For further information,

/**/ RNS Number : 8411F IQ-AI Limited 13 July 2023   13 July 2023 IQ-AI Ltd (“IQ-AI” or the “Company”)   Orphan Drug Designation for GaM in Pediatric GBM    Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), today announced the U.S. Food and Drug Administration (US FDA) has

/**/ RNS Number : 3655A IQ-AI Limited 23 May 2023     IQ-AI Limited (“IQ-AI” or the “Company”)   Result of AGM   IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.   The Directors of the Company accept responsibility for the contents of

/**/ RNS Number : 2406A IQ-AI Limited 23 May 2023     IQ-AI Limited (“IQ-AI” or the “Company”)   AGM Statement   IQ-AI Limited is due to hold its AGM today. At the AGM, the Chairman will announce the following:   •             Over 200 more datasets have been received in collaboration with Phoenix Children’s Hospital.

/**/ RNS Number : 3203Y IQ-AI Limited 03 May 2023     IQ-AI Ltd (“IQ-AI” or the “Company”)   Notice of AGM   IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 23 May 2023

/**/ RNS Number : 4520X IQ-AI Limited 26 April 2023   26 April 2023   IQ-AI Ltd (“IQ-AI” or the “Company”)   Publication of Annual Report   The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2022.   The Annual Report will be available

/**/ RNS Number : 3886R IQ-AI Limited 28 February 2023   IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating GBM IQ-AI Limited, (LSE: IQAI) (OTCQB: IQAIF), is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium

/**/ RNS Number : 1496M IQ-AI Limited 10 January 2023   IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS   IQ-AI Limited (“IQAI”) (LSE: IQAI) (OTCQB: IQAIF) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly-owned subsidiary Imaging Biometrics (the “Company”), covering several material

/**/ RNS Number : 4535I IQ-AI Limited 02 December 2022   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to